Tobacco and nicotine product testing

Nicotine and Tobacco Research

Volumn 14, Issue 1, 2012, Pages 7-17

  Hatsukami, Dorothy K ^a   Biener, Lois ^b   Leischow, Scott J ^c   Zeller, Mitch R ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d PINNEY ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

CIGARETTE SMOKING; CLINICAL RESEARCH; CONSUMER; DRUG DELIVERY SYSTEM; EXPOSURE; GOVERNMENT REGULATION; HEALTH BELIEF; HEALTH HAZARD; HUMAN; LAW; LEGAL LIABILITY; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODUCT SAFETY; REVIEW; SMOKING CESSATION; TOBACCO; TOBACCO DEPENDENCE;

EID: 84855167133     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntr027     Document Type: Review

References (58)

1. Benowitz, N. L., Hall, S. M., Stewart, S., Wilson, M., Dempsey, D., & Jacob, P., III. (2007). Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiology Biomarkers & Prevention, 16, 2479-2485. doi:16/11/2479 [pii]
2. Benowitz, N. L., & Henningfield, J. E. (1994). Establishing a nicotine threshold for addiction. The implications for tobacco regulation. New England Journal of Medicine, 331, 123-125.
3. Benowitz, N. L., Jacob, P., III., & Herrera, B. (2006). Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clinical Pharmacology and Therapeutics, 80, 703-714. doi:S0009-9236(06)00385-7 [pii].
4. Borland, R., Yong, H. H., King, B., Cummings, K. M., Fong, G. T., Elton-Marshall, T., et al. (2004). Use of and beliefs about light cigarettes in four countries: Findings from the International Tobacco Control Policy Evaluation Survey. Nicotine & Tobacco Research, 6(Suppl. 3), S311-S321.
5. Brownawell A. M. (Ed.) (2007) Biological effects assessment in the evaluation of potential reduced-risk tobacco products. Bethesda, MD: Life Sciences Research Office.
6. Burns, D., Dybing, E., Gray, N., Hecht, S., Anderson, C., Sanner, T., et al. (2008). Mandated lowering of toxicants in cigarette smoke: A description of the World Health Organization TobReg proposal. Tobacco Control, 17, 132-141.
7. Carter, L. P., Stitzer, M. L., Henningfield, J. E., O'Connor, R. J., Cummings, K. M., & Hatsukami, D. K. (2009). Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiology Biomarkers & Prevention, 18, 3241-3262. doi:18/12/3241 [pii] 10.1158/1055-9965.EPI-09-0948
8. Carter, S. M., & Chapman, S. (2006). Smokers and non-smokers talk about regulatory options in tobacco control. Tobacco Control, 15, 398-404.
9. Chapman, S., Wilson, D., & Wakefield, M. (1986). Smokers' understandings of cigarette yield labels. Medical Journal of Australia, 145, 376-379.
10. Cummings, K. M., Hyland, A., Bansal, M. A., & Giovino, G. A. (2004). What do Marlboro Lights smokers know about low-tar cigarettes? Nicotine & Tobacco Research, 6(Suppl. 3), S323-S332.
11. Environics Research Group Limited. (2003). Toxics information on cigarette packaging. Results of a survery of smokers, Final report prepared by Health Canada, Toronto, Canada.
12. Ferno, O. (1973). A substitute for tobacco smoking. Psychopharmacologia, 31, 201-204.
13. Fiore, M. C., Jaen, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J., et al. (2008). Treating tobacco use and dependence: 2008 update clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service.
14. Gray, N., Henningfield, J. E., Benowitz, N. L., Connolly, G. N., Dresler, C., Fagerstrom, K., et al. (2005). Toward a comprehensive long term nicotine policy. Tobacco Control, 14, 161-165.
15. Hanson, K., O'Connor, R., & Hatsukami, D. (2009). Measures for assessing subjective effects of potential reduced-exposure products. Cancer Epidemiology Biomarkers & Prevention, 18, 3209-3224. doi:18/12/3209 [pii] 10.1158/1055-9965.EPI-09-0971
16. Hatsukami, D., Benowitz, N. L., Rennard, S. I., Oncken, C., & Hecht, S. S. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine & Tobacco Research, 8, 599-622.
17. Hatsukami, D., Ebbert, J. O., Feuer, R. M., Stepanov, I., & Hecht, S. S. (2007). Changing smokeless tobacco products new tobacco-delivery systems. American Journal of Preventive Medicine, 33(6 Suppl.), S368-S378. doi:S0749-3797(07)00564-8 [pii] 10.1016/j.amepre.2007.09.005
18. Hatsukami, D., Giovino, G. A., Eissenberg, T., Clark, P. I., Lawrence, D., & Leischow, S. (2005). Methods to assess potential reduced exposure products. Nicotine & Tobacco Research, 7, 827-844. doi:G7V708275572538J [pii] 10.1080/14622200500266015
19. Hatsukami, D., Hanson, K., Briggs, A., Parascandola, M., Genkinger, J. M., O'Connor, R., et al. (2009). Clinical trials methods for evaluation of potential reduced exposure products. Cancer Epidemiology Biomarkers & Prevention, 18, 3143-3195. doi:18/12/3143 [pii] 10.1158/1055-9965.EPI-09-0654
20. Hatsukami, D., Kotlyar, M., Hertsgaard, L. A., Zhang, Y., Carmella, S. G., Jensen, J. A., et al. (2010). Reduced nicotine content cigarettes: Effects on toxicant exposure, dependence and cessation. Addiction, 105, 343-355. doi:ADD2780 [pii] 10.1111/j.1360-0443.2009.02780.x
21. Hatsukami, D., Lemmonds, C., & Tomar, S. (2004). Smokeless tobacco use: Harm reduction or induction approach? Preventive Medicine, 38, 309-317.
22. Hatsukami, D., & Parascandola, M. (2010). Tobacco harm reduction. In P. Boyle, N. Gray, J. Henningfield, J. Seffrin & W. Zatonski (Eds), Tobacco: Science, policy and public health. Oxford: Oxford University Press.
23. Hatsukami, D., Perkins, K. A., Lesage, M. G., Ashley, D. L., Henningfield, J. E., Benowitz, N. L., et al. (2010). Nicotine reduction revisited: Science and future directions. Tobacco Control, 19, e1-e10. doi:19/5/e1 [pii] 10.1136/tc.2009.035584
24. Hecht, S. S. (2011). Research opportunities related to establishing standards for tobacco products under the family smoking prevention and tobacco control act. Nicotine & Tobacco Research. Advance online publication. doi:10.1093/ntr/ntq216
25. Hecht, S. S., Murphy, S. E., Carmella, S. G., Zimmerman, C. L., Losey, L., Kramarczuk, I., et al. (2004). Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. Journal of the National Cancer Institute, 96, 107-115.
26. Henningfield, J., Benowitz, N. L., Slade, J., Houston, T. P., Davis, R. M., & Deitchman, S. D. (1998). Reducing the addictiveness of cigarettes. Council on scientific affairs, American Medical Association. Tobacco Control, 7, 281-293.
27. Hughes, J. R., & Carpenter, M. J. (2006). Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine & Tobacco Research, 8, 739-749.
28. Ipsos-Eureka Social Research Institute. (2009). Public health value of disclosed cigarette ingredients and emission values. Sydney, Australia: Department of Health and Aging.
29. Jarvis, M. J., Boreham, R., Primatesta, P., Feyerabend, C., & Bryant, A. (2001). Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: Evidence from a representative population survey. Journal of the National Cancer Institute, 93, 134-138.
30. Johnson, M. D., Schilz, J., Djordjevic, M. V., Rice, J. R., & Shields, P. G. (2009). Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. Cancer Epidemiology Biomarkers & Prevention, 18, 3263-3304. doi:18/12/3263 [pii] 10.1158/1055-9965.EPI-09-0965
31. Kozlowski, L. T., & Pillitteri, J. L. (2001). Beliefs about "Light" and "Ultra Light" cigarettes and efforts to change those beliefs: An overview of early efforts and published research.. Tobacco Control, 10(Suppl. 1), i12-i16.
32. Leischow, S. J. (1994). The nicotine vaporizer. Health Values, 18, 4-9.
33. Leischow, S. J., Zeller, M., & Backinger, C. L. (2011). Research priorities and infrastructure needs of the family smoking prevention and tobacco control act: science to inform FDA policy. Nicotine & Tobacco Research. Advance online publication. doi:10.1093/ntr/ntr057
34. Lewis K. D. (Ed.) (2007). Exposure assessment in the evaluation of potential reduced-risk tobacco products. Bethesda, MD: Life Sciences Research Office.
35. McNeill, A., Foulds, J., & Bates, C. (2001). Regulation of nicotine replacement therapies (NRT): A critique of current practice. Addiction, 96, 1757-1768. doi:10.1080/09652140120089508
36. National Cancer Institute. (2001). Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No. 13 (Vol. NIH Pub. No. 02-5074). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
37. O'Connor, R. J., Cummings, K. M., Giovino, G. A., McNeill, A., & Kozlowski, L. T. (2006). How did UK cigarette makers reduce tar to 10 mg or less? British Medical Journal, 332, 302. doi:332/7536/302 [pii] 10.1136/bmj.332.7536.302
38. O'Connor, R. J., Cummings, K. M., Rees, V. W., Connolly, G. N., Norton, K. J., Sweanor, D., et al. (2009). Surveillance methods for identifying, characterizing, and monitoring tobacco products: Potential reduced exposure products as an example. Cancer Epidemiology Biomarkers & Prevention, 18, 3334-3348. doi:18/12/3334 [pii] 10.1158/1055-9965.EPI-09-0429
39. Phoenix Strategic Perspectives. (2006). Canadians' understanding of the chemistry behind cigarette smoking and its impact on health: Report on Qualitative and Quantitative Research. Ottawa, Canada: Health Canada.
40. Pollay, R. W., & Dewhirst, T. (2002). The dark side of marketing seemingly "Light" cigarettes: Successful images and failed fact. Tobacco Control, 11(Suppl. 1), I18-I31.
41. Rees, V. W., Kreslake, J. M., Cummings, K. M., O'Connor, R. J., Hatsukami, D. K., Parascandola, M., et al. (2009). Assessing consumer responses to potential reduced-exposure tobacco products: A review of tobacco industry and independent research methods. Cancer Epidemiology Biomarkers & Prevention, 18, 3225-3240. doi:18/12/3225 [pii] 10.1158/1055-9965.EPI-09-0946
42. Rees, V. W., Kreslake, J. M., O'Connor, R. J., Cummings, K. M., Parascandola, M., Hatsukami, D., et al. (2009). Methods used in internal industry clinical trials to assess tobacco risk reduction. Cancer Epidemiology Biomarkers & Prevention, 18, 3196-3208. doi:18/12/3196 [pii] 10.1158/1055-9965.EPI-09-0819
43. Richter, P., Hodge, K., Stanfill, S., Zhang, L., & Watson, C. (2008). Surveillance of moist snuff total nicotine, pH, moisture, un-ionized nicotine, and tobacco-specific nitrosamine content. Nicotine & Tobacco Research, 10, 1645-1652.
44. Rodgman, A., & Perfetti, T. A. (2009). The chemical components of tobacco and tobacco smoke. Retrieved from http://marc.crcnetbase.com/isbn/9781420078848
45. Royal College of Physicians. (2007). Harm reduction in nicotine addiction. Helping people who can't quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London, UK: Author.
46. Samet, J. M., McMichael, G. H., & Wilcox, A. J. (2010). The use of epidemiological evidence in the compensation of veterans. Annals of Epidemiology, 20, 421-427. doi:10.1016/j.annepidem.2010.03.002
47. Shiffman, S., Pillitteri, J. L., Burton, S. L., Rohay, J. M., & Gitchell, J. G. (2001a). Effect of health messages about "Light" and "Ultra Light" cigarettes on beliefs and quitting intent. Tobacco Control, 10(Suppl. 1), i24-i32.
48. Shiffman, S., Pillitteri, J. L., Burton, S. L., Rohay, J. M., & Gitchell, J. G. (2001b). Smokers' beliefs about "Light" and "Ultra Light" cigarettes. Tobacco Control, 10(Suppl. 1), i17-i23.
49. Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 3.
50. St. Hilaire C. (Ed.) (2007). Scientific methods to evaluate potential reduced-risk tobacco products. Bethesda, MD: Life Sciences Research Office.
51. Stepanov, I., Jensen, J., Hatsukami, D., & Hecht, S. S. (2008). New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levels. Nicotine & Tobacco Research, 10, 1773-1782. doi:10.1093/ntr/NTN004
52. Stratton K., Shetty P., Wallace R. & Bondurant S. (Eds.) (2001). Clearing the smoke: Assessing the science base for tobacco harm reduction. Institute of Medicine. Washington, DC: National Academy Press.
53. Sweanor, D., Alcabes, P., & Drucker, E. (2007). Tobacco harm reduction: How rational public policy could transform a pandemic. International Journal on Drug Policy, 18, 70-74. doi:S0955-3959(06)00241-6 [pii]
54. Wakefield, M., Morley, C., Horan, J. K., & Cummings, K. M. (2002). The cigarette pack as image: New evidence from tobacco industry documents. Tobacco Control, 11(Suppl. 1), I73-I80.
55. Warner, K. E. (2009). Tobacco research methodology: First things first. Cancer Epidemiology Biomarkers & Prevention, 18, 3140-3142. doi:18/12/3140 [pii]
56. World Health Organization. (2008). The scientific basis of tobacco product regulation: Second report of a WHO study group. Geneva, Switzerland: Author.
57. World Health Organization Study Group on Tobacco Product Regulation. (2003). Guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing. Retrieved from www.who.int/tobacco/global_interaction/tobreg/goa_2003_principles/en
58. Zeller, M., & Hatsukami, D., & Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The strategic dialogue on tobacco harm reduction: A vision and blueprint for action in the US. Tobacco Control, 18, 324-332. doi:tc.2008.027318 [pii]